PATENT CLAIM ANALYSIS

Application Number: 15576091
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-07
Patent Classification: ["435", "101000"]

Abstract:
The present invention relates to a hypoxia-treated mesenchymal stem cell and the use thereof. The present invention discloses for the first time that treating mesenchymal stem cells with hypoxia can significantly promote alleviating or therapeutic effects of mesenchymal stem cells on inflammatory diseases. The present invention also discloses that the hypoxia-treated mesenchymal stem cell is capable of producing insulin-like growth factor-2, which plays a central role in the treatment of inflammatory diseases with the hypoxia-treated mesenchymal stem cell.

Claim (Index 2):
The method of  claim 1 , wherein the inflammatory disease includes multiple sclerosis or inflammatory bowel disease.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 88.0
- Lexical Diversity: 1.67347
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14413290', '15656473', '13905526', '15121569', '13691349']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6752600123619817
- 35 USC 102 Novelty (BERT): 0.5295761911190257
- Combined Prediction Score: 0.6606916302376862
- Mean Citation Score: 346.66624599999994
- Max Citation Score: 357.4761
- Similarity Product: 201.4612370144248

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test